Salīdzināt metodes
Apskatiet izvēlētās metodes blakus; rindas, kas atšķiras, ir izceltas.
| Gada dzīvības kvalitātes koriģētais gads (QALY)× | Analīze izmaksu un efektivitātes (CEA)× | |
|---|---|---|
| Nozare | Veselības ekonomika | Veselības ekonomika |
| Saime | Process / pipeline | Process / pipeline |
| Izcelsmes gads≠ | 1985 | 1984 |
| Autors≠ | Alan Williams (Health Economics Research Centre, Oxford University) | Drummond & Stoddart (Health Economics Research Group, McMaster University) |
| Tips | Method | Method |
| Pirmavots≠ | Kind, P. (1989). The EuroQol instrument: an index of health-related quality of life. In B. Teeling Smith (Ed.), Measuring health: a practical approach. Chichester: Wiley. link ↗ | Gold, M. R., Siegel, J. E., Russell, L. B., & Weinstein, M. C. (Eds.). (1996). Cost-Effectiveness in Health and Medicine. New York: Oxford University Press. link ↗ |
| Citi nosaukumi≠ | QALY, health utility measure | CEA, ICER, Incremental Cost-Effectiveness Ratio |
| Saistītās | 5 | 5 |
| Kopsavilkums≠ | A QALY measures health benefit as utility weight (0 = death, 1 = perfect health) multiplied by time lived. Developed by Alan Williams in 1985, QALYs enable comparison of disparate health interventions on a common metric. Used globally by health technology assessment bodies—NICE (UK), HAS (France), CADTH (Canada), WHO—to decide which treatments deserve public funding. | Cost-effectiveness analysis compares the incremental cost per unit of health benefit gained by one intervention relative to a comparator (standard care or best alternative). Developed rigorously in the 1980s by Drummond, Stoddart, and colleagues, CEA is now the standard framework for technology appraisal globally. NICE, HAS, CADTH, and other health technology assessment bodies use CEA to decide which treatments warrant public funding and at what price. |
| ScholarGateDatu kopa ↗ |
|
|